Newsletter Subject

[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

From

marketinsiderspress.com

Email Address

editor@marketinsiderspress.com

Sent On

Mon, Oct 3, 2022 04:52 PM

Email Preheader Text

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please clic

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( [marketinside...] --------------------------------------------------------------- [Investors See Opportunity in Huge Global Demand for Lithium]( [Put this company on your investing radar today.]([aff_i?offer_...] --------------------------------------------------------------- October 03, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers of all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- [GRAPHITE: "Essential for America's National Defense"]( [28723724-9dc...](Did you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider. [Discover Who's Poised to Benefit In The U.S. vs. China Energy War]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [Prothena, PRTA]( Recent Analyst Action: Jay Olson, analyst at Oppenheimer, reiterates coverage on [Prothena (PRTA)](in the Healthcare sector with a Buy rating and a price target of $110.00 (4 days ago). - Recent Price: $61.45 - Average Analyst Price Target: $74.71 (21.58%) - Market Cap: $2.84B [TipRanks.com]( also reports that [Prothena](currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $74.71. The target pricing ranges from a high forecast of $110.00 down to a low forecast of $52.00. [Prothena (PRTA)](’s last closing price was $61.45 which would put the average price target at $74.71. Here are 3rd party ratings for [PRTA](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 34% (85 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Squeeze this "cash spout" for instant gas, grocery, rent money]( [9bab8038-2ca...](What if instead of loosing money every time you fill up at the pump… there was a way to throw the pump in reverse and fill up with cash every time you pull the handle. This "cash spout" exists in a hidden corner of the stock market. It FORCES instant payouts out of every trade. [Click here to see how it works.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Senti Biosciences, SNTI]( Recent Analyst Action: Greg Harrison, analyst at Bank of America Securities, reiterates coverage on [Senti Biosciences (SNTI)](in the Healthcare sector with a Buy rating and a price target of $7.00 (4 days ago). - Recent Price: $2.31 - Average Analyst Price Target: $7.00 (203.03%) - Market Cap: $107.43M [TipRanks.com]( also reports that [Senti Biosciences](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $7.00. The target pricing ranges from a high forecast of $7.00 down to a low forecast of $7.00. [Senti Biosciences (SNTI)](’s last closing price was $2.31 which would put the average price target at $7.00. Here are 3rd party ratings for [SNTI](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Top 34% (85 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Harrow Health, HROW]( Recent Analyst Action: Sahil Kazmi, analyst at B.Riley Financial, reiterates coverage on [Harrow Health (HROW)](in the Healthcare sector with a Buy rating and a price target of $17.00 (6 days ago). - Recent Price: $12.97 - Average Analyst Price Target: $17.00 (31.07%) - Market Cap: $326.73M [TipRanks.com]( also reports that [Harrow Health](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $17.00. The target pricing ranges from a high forecast of $17.00 down to a low forecast of $17.00. [Harrow Health (HROW)](’s last closing price was $12.97 which would put the average price target at $17.00. Here are 3rd party ratings for [HROW](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Sell, Bottom 35% (162 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [#1 Stock for Rising Interest Rates]( [790f5013-769...](There's no hiding from these interest rate hikes. [And only one industry is set to reap all the rewards.]( This industry has produced 26% average returns every year for the past 22 years. Today I want to tell you about my #1 stock to buy right now. It checks the following boxes... Pays a high 8% dividend, increasing their dividend by 37.5 % on average. The stock is trading at dirt cheap levels around $14. This industry is stronger 'than ever' as the Fed raises rates. [Click here to see this #1 stock.](//trailer.web-view.net/Links/0X1BCCE471CA9D088BDA3185587FD9F5F5E007A54E3AE8BF2BE95C6D5E58FE91E7C0394156C82D92D7108B3024E177FD95502FFCDDDB890F0B001B444F7491C4D0F598CD369566B7DD.htm [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [AKOUOS, AKUS]( Recent Analyst Action: Sami Corwin, analyst at William Blair, reiterates coverage on [AKOUOS (AKUS)](in the Healthcare sector with a Buy rating and a price target of $12.00 (4 days ago). - Recent Price: $6.82 - Average Analyst Price Target: $24.00 (251.91%) - Market Cap: $249.44M [TipRanks.com]( also reports that [AKOUOS](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $24.00. The target pricing ranges from a high forecast of $35.00 down to a low forecast of $12.00. [AKOUOS (AKUS)](’s last closing price was $6.82 which would put the average price target at $24.00. Here are 3rd party ratings for [AKUS](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: buy - Zacks.com: Buy, Top 34% (85 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Coeur Mining, CDE]( Recent Analyst Action: Ryan Thompson, analyst at BMO Capital, reiterates coverage on [Coeur Mining (CDE)](in the Basic Materials sector with a Hold rating and a price target of $4.00 (1 week ago). - Recent Price: $3.91 - Average Analyst Price Target: $4.00 (2.30%) - Market Cap: $960.57M [TipRanks.com]( also reports that [Coeur Mining](currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $4.00. The target pricing ranges from a high forecast of $4.50 down to a low forecast of $3.50. [Coeur Mining (CDE)](’s last closing price was $3.91 which would put the average price target at $4.00. Here are 3rd party ratings for [CDE](: - TipRanks.com: Hold - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Strong Sell, Bottom 27% (183 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush."]( [f5987313-06a...](Experts predict that the global lithium market will balloon by 500%. That's wonderful news for investors, because a "sure-thing" like this appears once in a lifetime. And this small-cap company just snagged what could be one of the world's largest lithium deposits. [Discover This Company's MASSIVE Lithium Opportunity!]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Gatos Silver, GATO]( Recent Analyst Action: Ryan Thompson, analyst at BMO Capital, reiterates coverage on [Gatos Silver (GATO)](in the Basic Materials sector with a Hold rating and a price target of $4.00 (1 month ago). - Recent Price: $3.18 - Average Analyst Price Target: $4.00 (25.79%) - Market Cap: $185.28M [TipRanks.com]( also reports that [Gatos Silver](currently has 2 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $4.00. The target pricing ranges from a high forecast of $4.00 down to a low forecast of $4.00. [Gatos Silver (GATO)](’s last closing price was $3.18 which would put the average price target at $4.00. Here are 3rd party ratings for [GATO](: - TipRanks.com: Hold - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: n/a, n/a [Click here for chart >>]( -------------------------------------------------------------------------- [Karyopharm Therapeutics, KPTI]( Recent Analyst Action: Michael Ulz, analyst at Morgan Stanley, reiterates coverage on [Karyopharm Therapeutics (KPTI)](in the Healthcare sector with a Hold rating and a price target of $7.00 (3 weeks ago). - Recent Price: $5.7 - Average Analyst Price Target: $9.29 (62.98%) - Market Cap: $435.74M [TipRanks.com]( also reports that [Karyopharm Therapeutics](currently has 7 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $9.29. The target pricing ranges from a high forecast of $18.00 down to a low forecast of $5.00. [Karyopharm Therapeutics (KPTI)](’s last closing price was $5.7 which would put the average price target at $9.29. Here are 3rd party ratings for [KPTI](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 33% (82 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [The Biggest "Missing Ingredient" in the $7 Trillion EV Market]( [c732b483-3e4...](China has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market. [Don't Miss Your Opportunity to Benefit from This Breaking News]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- And there you have it--7 Five Day Gainers of all US Exchanges. Sincerely, The Editor, MarketInsidersPress.com Market Insider Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software

Marketing emails from marketinsiderspress.com

View More
Sent On

09/05/2024

Sent On

09/05/2024

Sent On

09/05/2024

Sent On

08/05/2024

Sent On

08/05/2024

Sent On

08/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.